Sodium-glucose cotransporter-2 inhibitors: where and when?

被引：1
作者：
Cowie, Martin R. [1 ]
机构：
[1] Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Hosp, London, England
来源：
FUTURE CARDIOLOGY | 2020年 / 17卷 / 03期
关键词：
cardiovascular disease; chronic kidney disease; diabetes mellitus; guidelines; heart failure; implementation; outcome trials; SGLT2; inhibitors; REDUCED EJECTION FRACTION; HEART-FAILURE;
D O I：
10.2217/fca-2020-0207
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Tweetable abstract Sodium-glucose cotransporter-2 inhibitors not only improve glycaemic control in Type 2 diabetes mellitus but convincingly improve outcome for everyone with HFrEF and albuminuric kidney disease. Trials then license - now all we need is implementation
引用
收藏
页码：403 / 406
页数：4
相关论文
共 11 条
  • [1] 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
    Cosentino, Francesco
    Grant, Peter J.
    Aboyans, Victor
    Bailey, Clifford J.
    Ceriello, Antonio
    Delgado, Victoria
    Federici, Massimo
    Filippatos, Gerasimos
    Grobbee, Diederick E.
    Hansen, Tina Birgitte
    Huikuri, Heikki, V
    Johansson, Isabelle
    Juni, Peter
    Lettino, Maddalena
    Marx, Nikolaus
    Mellbin, Linda G.
    Ostgren, Carl J.
    Rocca, Bianca
    Roffi, Marco
    Sattar, Naveed
    Seferovic, Petar M.
    Sousa-Uva, Miguel
    Valensi, Paul
    Wheeler, David C.
    Piepoli, Massimo Francesco
    Birkeland, Kare, I
    Adamopoulos, Stamatis
    Ajjan, Ramzi
    Avogaro, Angelo
    Baigent, Colin
    Brodmann, Marianne
    Bueno, Hector
    Ceconi, Claudio
    Chioncel, Ovidiu
    Coats, Andrew
    Collet, Jean-Philippe
    Collins, Peter
    Cosyns, Bernard
    Di Mario, Carlo
    Fisher, Miles
    Fitzsimons, Donna
    Halvorsen, Sigrun
    Hansen, Dominique
    Hoes, Arno
    Holt, Richard I. G.
    Home, Philip
    Katus, Hugo A.
    Khunti, Kamlesh
    Komajda, Michel
    Lambrinou, Ekaterini
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 (02) : 255 - 323
  • [2] DAPA-HF: does dapagliflozin provide 'bang for your buck' as a treatment forheart failure with reduced ejection fraction?
    Cowie, Martin R.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (11) : 2157 - 2159
  • [3] SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
    Cowie, Martin R.
    Fisher, Miles
    [J]. NATURE REVIEWS CARDIOLOGY, 2020, 17 (12) : 761 - 772
  • [4] 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
    Das, Sandeep R.
    Everett, Brendan M.
    Birtcher, Kim K.
    Brown, Jenifer M.
    Cefalu, William T.
    Januzzi, James L., Jr.
    Kalyani, Rita Rastogi
    Kosiborod, Mikhail
    Magwire, Melissa L.
    Morris, Pamela B.
    Sperling, Laurence S.
    Ahmad, Tariq
    Hucker, William
    Kumbhani, Dharam J.
    Marine, Joseph E.
    Piana, Robert N.
    Rao, Sunil V.
    Scherrer-Crosbie, Marielle
    Watson, Karol E.
    Wiggins, Barbara S.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (24) : 3200 - 3223
  • [5] Dapagliflozin in Patients with Chronic Kidney Disease
    Heerspink, Hiddo J. L.
    Stefansson, Bergur V.
    Correa-Rotter, Ricardo
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan-Fan
    Mann, Johannes F. E.
    McMurray, John J. V.
    Lindberg, Magnus
    Rossing, Peter
    Sjostrom, C. David
    Toto, Roberto D.
    Langkilde, Anna-Maria
    Wheeler, David C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) : 1436 - 1446
  • [6] Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey
    Komajda, Michel
    Anker, Stefan D.
    Cowie, Martin R.
    Filippatos, Gerasimos S.
    Mengelle, Bastian
    Ponikowski, Piotr
    Tavazzi, Luigi
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (05) : 514 - 522
  • [7] Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis ofDAPA-HF
    McEwan, Phil
    Darlington, Oliver
    McMurray, John J. V.
    Jhund, Pardeep S.
    Docherty, Kieran F.
    Boehm, Michael
    Petrie, Mark C.
    Bergenheim, Klas
    Qin, Lei
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (11) : 2147 - 2156
  • [8] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
    McMurray, J. J. V.
    Solomon, S. D.
    Inzucchi, S. E.
    Kober, L.
    Kosiborod, M. N.
    Martinez, F. A.
    Ponikowski, P.
    Sabatine, M. S.
    Anand, I. S.
    Belohlavek, J.
    Bohm, M.
    Chiang, C. -E.
    Chopra, V. K.
    de Boer, R. A.
    Desai, A. S.
    Diez, M.
    Drozdz, J.
    Dukat, A.
    Ge, J.
    Howlett, J. G.
    Katova, T.
    Kitakaze, M.
    Ljungman, C. E. A.
    Merkely, B.
    Nicolau, J. C.
    O'Meara, E.
    Petrie, M. C.
    Vinh, P. N.
    Schou, M.
    Tereshchenko, S.
    Verma, S.
    Held, C.
    DeMets, D. L.
    Docherty, K. F.
    Jhund, P. S.
    Bengtsson, O.
    Sjostrand, M.
    Langkilde, A. -M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) : 1995 - 2008
  • [9] Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
    Packer, Milton
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Pocock, Stuart J.
    Carson, Peter
    Januzzi, James
    Verma, Subodh
    Tsutsui, Hiroyuki
    Brueckmann, Martina
    Jamal, Waheed
    Kimura, Karen
    Schnee, Janet
    Zeller, Cordula
    Cotton, Daniel
    Bocchi, Edimar
    Boehm, Michael
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure, Eduardo
    Giannetti, Nadia
    Janssens, Stefan
    Zhang, Jian
    Juanatey, Jose R. Gonzalez
    Kaul, Sanjay
    Brunner-La Rocca, Hans-Peter
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio
    Pina, Ileana
    Ponikowski, Piotr
    Sattar, Naveed
    Senni, Michele
    Seronde, Marie-France
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Wanner, Christoph
    Zannad, Faiez
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) : 1413 - 1424
  • [10] Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
    Perkovic, V.
    Jardine, M. J.
    Neal, B.
    Bompoint, S.
    Heerspink, H. J. L.
    Charytan, D. M.
    Edwards, R.
    Agarwal, R.
    Bakris, G.
    Bull, S.
    Cannon, C. P.
    Capuano, G.
    Chu, P. -L.
    De Zeeuw, D.
    Greene, T.
    Levin, A.
    Pollock, C.
    Wheeler, D. C.
    Yavin, Y.
    Zhang, H.
    Zinman, B.
    Meininger, G.
    Brenner, B. M.
    Mahaffey, K. W.
    McGuire, Darren K.
    Holman, Rury
    Home, Philip
    Scharfstein, Dan
    Parfrey, Patrick
    Shahinfar, Shahnaz
    August, Phyllis
    Chang, Tara
    Sinha, Arjun D.
    Januzzi, James
    Kolansky, Daniel
    Amerena, John
    Hillis, Graham
    Gorelick, Philip
    Kissela, Brett
    Kasner, Scott
    Lindley, Richard
    Fulcher, Greg
    Ounadjela, Souhila
    Hufert, Karina
    von Ingersleben, Gabriele
    Gaglia, Jason
    Harris, Ronald
    Hudson, Margo
    Turchin, Alexander
    Cheifetz, Adam
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) : 2295 - 2306
12